# BUY 💙 Tata Motors

## Reiterate BUY; strong pickup expected at JLR in H2

Auto & Auto Ancillaries > Company Update > October 8, 2024

JLR reported ~10% drop in Q2 wholesales at 87K units amid issues at a key aluminum vendor; however, it expects production and wholesales to grow strongly in H2 amid supply normalization. Commentary around volume rebound is encouragingly divergent from luxury peers, who have recently downgraded their outlook citing demand weakness in China. We reaffirm our positivity on the stock, given: i) structural improvements across operational parameters at JLR (on track for becoming net-debt free in FY25E), and ii) healthy India outlook (particularly in CVs amid impending cyclical recovery and strong margin uptick). TTMT's BS is healthy with least-demanding valuations among OEMs. We cut FY26E/27E EPS by ~2% (5%/10% revenue/PBT CAGR) on slight margin reduction, and reiterate BUY with unchanged SoTP-based TP of Rs1,175/sh.

Tata Motors: Finan	cial Snapsh	ot (Consoli	dated)		
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Revenue	3,459,670	4,379,278	4,471,046	4,671,852	4,944,347
EBITDA	318,296	595,603	628,700	674,040	716,478
Adj. PAT	7,336	323,981	227,124	274,059	299,176
Adj. EPS (Rs)	1.9	84.5	61.7	74.5	81.3
EBITDA margin (%)	9.2	13.6	14.1	14.4	14.5
EBITDA growth (%)	28.3	87.1	5.6	7.2	6.3
Adj. EPS growth (%)	0.0	1,199.7	(24.7)	20.7	9.2
RoE (%)	1.6	49.8	23.8	23.1	20.6
RoIC (%)	3.0	42.7	30.1	31.5	31.9
P/E (x)	484.4	11.0	15.0	12.5	11.4
EV/EBITDA (x)	13.3	6.6	6.1	5.5	5.0
P/B (x)	7.8	4.2	3.2	2.6	2.1
FCFF yield (%)	4.1	9.4	1.0	6.8	6.0

Source: Company, Emkay Research

## JLR: Expects strong improvement in H2 volumes on normalizing supplies

JLR reported Q2FY25 wholesale volumes of 87.3K units, down ~10% YoY/11% QoQ. Retails stood at 103K units (down 3% YoY, amid 22%/17% decline in Europe/China, respectively), against production of ~86K units (down 7% YoY). Notably, contribution of the most profitable models (*Range Rover, Range Rover Sport, and Defender*) stood at 67% vs 63.5% in Q2FY24. The decline in Q2 wholesales was due to production issues at a key aluminum supplier (already flagged in Q1); however, encouragingly, the company expects both production and wholesales to pick up strongly in H2FY25 as supplies normalize. This is in contrast to the recent outlook downgrades at peers like BMW and Mercedes-Benz amid muted demand in China.

### Strong structural improvements at JLR; deleveraging story largely intact

We highlight that JLR has delivered strong improvements across financial/operational parameters (*Exhibit 5*) over the past 5 years, despite flattish volumes amid a strong focus on profitability and leveraging the strength/image of its iconic brands ('House of Brands' approach). It expects to further deliver upon growth, profitability, and return ratios while also investing toward electrification (introduction of electric *Range Rover* next year, upcoming all-electric transition of Jaguar). We expect profitability at JLR to sustain with the deleveraging journey also on track (net-debt free in FY25E).

## India outlook healthy, driven by cyclical revival in CVs

India business outlook is improving – especially in CVs, where: i) H2FY24 offers a benign base (industry volumes were down 1% YoY in H2FY24 as against 18% growth in Q2FY24), and ii) expected catch-up in GoI infra spends (~63% growth YoY needed over Aug-Mar to meet budgeted targets), should lead to healthy demand revival for the coming year. This should kick-start a cyclical recovery in MHCVs after 2 largely-flattish years (FY23-25E); continued healthy fleet operator profitability and sustained pricing discipline is also seen driving ~270bps margin expansion over FY24-27E. While PV industry outlook remains soft amid slowing retails (industry volumes are flat YoY till September on YTD basis), and rising inventory/discounts, TTMT is relatively better placed due to new launches incl *Curvv* (we build 4% volume CAGR over FY24-27E).



### **TARGET PRICE (Rs): 1,175**

Target Price – 12M	Sep-25
Change in TP (%)	-
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	26.6
CMP (07-Oct-24) (Rs)	927.9
Stock Data	Ticker
52-week High (Rs)	1,179
52-week Low (Rs)	612
Shares outstanding (mn)	3,680.9
Market-cap (Rs bn)	3,887
Market-cap (USD mn)	46,288
Net-debt, FY25E (Rs mn)	430,286
ADTV-3M (mn shares)	14
ADTV-3M (Rs mn)	14,975.3
ADTV-3M (USD mn)	178.3
Free float (%)	53.6
Nifty-50	24,796
INR/USD	84.0
Shareholding, Sep-24	
Promoters (%)	41.9
FPIs/MFs (%)	
1113/1113 (70)	18.1/13.4

Price Performance										
(%)	1M	ЗМ	12M							
Absolute	(11.6)	(6.6)	49.5							
Rel. to Nifty	(11.4)	(8.4)	18.5							



#### Chirag Jain

chirag.jain@emkayglobal.com +91 22 6624 2428

### Jaimin Desai

jaimin.desai@emkayglobal.com +91 22 6612 1334

### Nandan Pradhan

nandan.pradhan@emkayglobal.com +91 22 6612 1238

### Omkar Rane

omkar.rane@emkayglobal.com +91 22 6624 2414

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 10/08/2024 03:10 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAYsGO>Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

## BMW recently downgraded outlook on CY24 deliveries and profitability amid supply issues at a vendor and muted demand in China (link)

"The Board of Management of BMW AG adjusted the guidance for the 2024 financial year today. This was triggered in part by additional headwinds in the Automotive Segment resulting from delivery stops and technical actions linked to the Integrated Braking System (IBS) that is provided by a supplier. The delivery stops for vehicles that are not already in customers' hands will have a negative worldwide sales effect in the second half of the year. The IBS-related technical actions impact over 1.5 million vehicles and result in additional warranty costs in a high three-digit million amount in the third quarter. In parallel to this effect, the ongoing muted demand in China is affecting sales volumes. Despite stimulus measures from the government, consumer sentiment remains weak. Considering these developments in the Automotive Segment outlined above, the BMW Group has adjusted the guidance for the 2024 financial year as follows:

- A slight decrease in deliveries versus previous year (previously: slight increase).
- An EBIT margin for 2024 in a corridor from 6% to 7% (previously: 8% to 10%).
- Return on Capital Employed (RoCE) between 11% and 13% (previously: 15% to 20%).

## Mercedes-Benz also recently cut its margin outlook citing weakness in China

"There is a tremendous amount of cautiousness, I'm trying to say this diplomatically... How long will that go on? I don't know, but I remain cautious for the foreseeable future on China."

Ola Kaellenius, CEO, Mercedes Benz (link)

Exhibit 1: China is a bigger market for BMW and Mercedes Benz (forms ~32/~36% of global volumes) than for JLR (~24% of retails)												
China - contribution (%)	CY18/FY19	CY19/FY20	CY20/FY21	CY21/FY22	CY22/FY23	CY23/FY24	H1CY24/Q1FY25					
BMW Group deliveries	25.6	28.6	33.5	33.6	33.1	32.4	31.0					
Mercedes-Benz Cars	28.4	29.1	36.3	37.8	36.9	36.1	35.6					
JLR retails incl. Chery JLR	17.1	17.7	25.3	25.4	25.7	24.1	22.0					


Source: Company, Emkay Research

## Notably, JLR's commentary on China has been relatively stronger


"So it's certainly more difficult and more difficult at the lower price points in China at the moment. However, the import business we still see as strong. We don't measure or refer to market share, but we note that our sales are increasing YoY in China. So it reflects the strength of the brands, particularly Range Rover and Defender. We are paying close attention to it as there are certainly signals that demand is not at the level that we would like to see it going forward, and it will be a focal point for us for the balance of the year to make sure that we take the necessary action. So it is absolutely a focal point for us."

Comments by Richard Molyneux, CFO, JLR in Q1FY25 (link)

rch is also available Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singa analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore. s on Distribution. In Singapore, this research report or research Exhibit 2: JLR – Overall China premium car market seen remaining largely stable over CY23-25, with rising share of EVs



Source: JLR 2024 Analyst Meet (link), Emkay Research



Source: JLR 2024 Analyst Meet (link), Emkay Research

## Exhibit 4: JLR in Q1FY25 maintained its FY25 outlook with regards to EBIT margin and net-cash BS

## Outlook

- · Global demand is likely to remain muted. Commodities are likely to remain range bound.
- · We are likely to witness constrained production in Q2 and Q3 reflecting the annual summer plant shutdown and floods at a key aluminum supplier.
- As we work towards mitigation and recovery, we will hold our guidance on our key full year financial deliverables of >8.5% EBIT and achieving net cash

## **Our Reimagine journey continues**

	Q1 FY25 ACTUAL	FY25 OUTLOOK	FY26 OUTLOOK	LONG-TERM VISION
REVENUE	£7.3b	£30b	>	c. £38b
EBIT MARGIN	8.9%	≥8.5%	10%	c. 15%
INVESTMENT	£951m	£3.5b	>	c. £4.0b
FREE CASHFLOW	£0.2b	c. £1.8b	=	c. £3.0b
NET CASH POSITIVE	£(1.0)b	Net cash positive	=	Strong balance sheet
ROCE	21.2%	>22%	>	>

Source: Company, Emkay Research

This report is intended for team emkay@whitemarquesolutions.com use and downloaded at 10/08/2024 03:10 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

	FY19	FY20	FY21	FY22	FY23	FY24
Product mix (%)	1115	1120		1.22	1125	
Land Rover	69	73	78	80	83	88
Of which: RR, RRS, Defender	25	24	36	40	48	63
Jaguar	31	27	22	20	17	12
ASP (GBP mn)	47,675	48,291	56,758	62,274	70,976	72,252
Growth YoY (%)		1	18	10	14	2
EBITDA margin (%)	8.2	8.9	12.8	10.3	11.3	15.9
EBITDA/unit (GBP)	3,900	4,307	7,281	6,445	8,000	11,512
EBIT margin (%)	(0.8)	0.6	2.8	(0.3)	2.3	8.4
EBIT/unit (GBP)	(360)	294	1,597	(163)	1,646	6,093
FCF (GBP mn)	(1,120)	(477)	485	(752)	978	2,269
Net Debt (GBP mn)	705	1,679	1,396	2,629	2,286	38
Net Debt/EBITDA (x)	0.4	0.8	0.6	1.4	0.9	0.0
RoE (%)	0.9	(2.8)	0.6	(16.3)	(1.2)	44.7
RoCE (Pre-tax, %)	(1.4)	1.3	4.9	(0.4)	4.9	23.9

Source: Company, Emkay Research





Exhibit 6: Centre's capex declined 18% YoY till Jul-24 vs budgeted


Source: CGA, Union Budget documents, Emkay Research

Exhibit 7: ...this should lead to strong ramp up in coming months; 63% YoY growth needed over Aug-Mar to meet Budget goals




Source: CGA, Union Budget documents, Emkay Research

Exhibit 8: MHCV industry grew 10% in H1FY24 vs 1% decline in H2FY24, thus presenting a benign base for H2FY25




Source: SIAM, Emkay Research

This report is intended for team emkay@whitemarquesolutions com use and downloaded at 10/08/2024 03:10 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.




Source: SIAM, Emkay Research

Exhibit 11: Pace of national highway construction this year has been the slowest since FY21 (hampered by elections)



Source: CMIE, Emkay Research

### Exhibit 13: Truck freight rates remain steady at elevated levels



Source: CMIE, Emkay Research

Source: CMIE, Emkay Research

# Implementation of DFC on the final leg of the Western Corridor (Nhava Sheva in Mumbai) getting delayed amid land acquisition, soil quality, and execution issues

"... the connectivity of DFC to Nhava Sheva. DFC is now connected only to Mundra and Pipavav. Now for Nhava Sheva, they are saying it will be end of 2024."

- Sanjay Swarup, Chairman & Managing Director, Container Corporation of India (Comments in Q2FY24; link)


"DFC to Nhava Sheva only 100 kilometers is remaining. And till now officially, we have come to know that by March 2025 they will be able to do it, which is a very, very optimistic target"

- Sanjay Swarup, Chairman & Managing Director, Container Corporation of India (Comments in Q1FY25; link)

itemarguesolutions.com use and downloaded at 10/08/2024 03:10 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 10: ...the Bus industry continues to post robust growth



Source: SIAM, Emkay Research

Source: CMIE, Emkay Research

digits; hit an all-time high recently

# Exhibit 12: Performance of the eight core industries, while below the recent peak, remains reasonably healthy




Exhibit 14: E-way bill generation continues to grow in double-

E-way bill per day

Oct-23 Jan-24 Apr-24 Jul-24 Jul-20 Jul-20 Jul-22 Jul-22

40

3.5

3.0 2.5

2.0

1.5

1.0 0.5


(Rs mn)

Performance of the eight core industries (Index; %)

"The last stretch of 104-km between Saphale and JNPT (Jawaharlal Nehru Port) was challenging from day one because there were a lot of land acquisition issues. Then, the problems with Tata Projects emerged, and they got slow in executing the project. We are not expecting WDFC to be fully operational before one year from now ... The quality of soil is not favourable. From the stability point of view, the contractor is facing issues. Because of the intervention of the Maharashtra government, we were able to complete the land acquisition last year - after a delay of almost 15-16 years."

Comments in media by a senior DFC official, in Jul-24 (link)

Exhibit 15: Sharp replacement-led upturn seen in truck industry volumes since FY21; average fleet age to start dipping below LTA going forward as replacement demand kicks in



Source: SIAM, Emkay Research

Vahan registrations	Sep-23	Oct-23	Nov-23	Dec-23	Jan-24	Feb-24	Mar-24	Apr-24	May-24	Jun-24	Jul-24	Aug-24	Sep-24
2W	1,313,896	1,513,001	2,257,482	1,452,670	1,463,831	1,443,571	1,533,738	1,648,340	1,538,293	1,379,394	1,447,881	1,341,652	1,201,661
PV	310,227	335,235	344,848	277,443	368,855	306,764	295,032	313,097	281,313	262,196	297,079	287,519	246,914
3W	63,481	63,481	63,481	63,481	90,562	87,346	96,053	72,254	88,423	84,451	99,091	93,816	94,232
MHCV	26,714	31,273	28,236	24,441	30,342	29,294	29,893	32,063	26,299	21,527	24,096	21,753	22,878
LCV	46,947	52,535	50,985	44,896	52,023	49,707	49,094	45,061	43,816	38,819	44,287	41,286	40,854
Tractors	47,417	53,524	52,972	70,222	81,754	69,173	70,704	50,012	62,190	63,235	71,042	58,761	55,594
Growth YoY (%)	Sep-23	Oct-23	Nov-23	Dec-23	Jan-24	Feb-24	Mar-24	Apr-24	May-24	Jun-24	Jul-24	Aug-24	Sep-24
2W	22	(12)	22	28	15	14	6	34	3	5	18	7	(9)
PV	15	(4)	16	1	12	11	(7)	17	0	(6)	12	(2)	(20)
3W	(4)	(8)	(19)	(5)	43	38	51	14	39	33	56	48	48
MHCV	8	19	(1)	0	2	(1)	(16)	(7)	(5)	(8)	7	(11)	(14)
LCV	(7)	0	(13)	(9)	(2)	3	(5)	1	3	(8)	2	(8)	(13)

Source: Vahan, Emkay Research


This report is intended for team.emkay@whitemarguesolutions.com use and downloaded at 10/08/2024\_03:10 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 17: Domestic CVs	s — TTMT has	gained m	arket sha	are in all	categorie	s, except	LCVs in	recent qu	arters			
Market share (%)	FY14	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	Q1FY2
Domestic Buses												
AL (incl. Switch)	38.6	36.1	44.6	37.5	38.2	41.3	45.3	38.2	32.1	28.0	34.5	33.4
ТТМТ	40.1	40.1	34.0	38.5	37.2	36.5	37.0	34.3	38.3	29.8	30.2	33.0
Others	21.3	23.8	21.4	24.0	24.6	22.2	17.7	27.5	29.6	42.2	35.3	33.6
Domestic Trucks												
Up to 16.2T												
AL	20.7	22.0	25.8	29.1	27.0	28.4	29.9	23.1	18.3	20.5	22.8	30.2
TTMT	51.8	49.6	46.2	42.1	41.2	42.1	40.2	40.7	46.2	40.5	33.8	35.4
VECV	24.4	25.5	24.9	25.1	29.4	26.9	26.3	30.9	30.5	34.2	36.3	28.3
Others	3.0	3.0	3.0	3.8	2.5	2.5	3.6	5.4	5.0	4.8	7.1	6.1
Above 16.2T												
AL	24.5	29.5	33.2	35.3	36.7	35.2	28.3	30.8	31.2	36.0	32.3	30.1
ТТМТ	64.0	61.3	59.5	56.1	54.9	56.4	60.2	58.0	58.2	52.5	52.8	54.1
VECV	3.8	3.4	3.5	4.4	3.9	3.8	7.2	8.7	8.4	9.6	12.5	13.3
Others	7.6	5.8	3.8	4.1	4.5	4.6	4.4	2.4	2.3	1.9	2.3	2.5
Domestic LCVs												
AL	6.3	6.7	7.5	7.5	8.2	8.6	9.1	11.4	11.0	11.0	11.2	11.1
TTMT	48.1	42.8	38.6	38.1	40.4	40.8	39.0	38.8	40.1	36.0	32.2	30.4
M&M	36.4	39.1	41.4	42.0	39.9	38.3	39.1	37.5	36.3	40.1	42.8	43.9
Others	9.2	11.4	12.5	12.5	11.5	12.2	12.9	12.3	12.6	12.8	13.7	14.

Source: SIAM, Emkay Research

Tata Motors (TTMT IN)






Source: Company, Emkay Research

Exhibit 19: TTMT has largely sustained its retail market share in the 14-15% range, though Aug/Sep-24 saw a decline to ~12-13%

India Equity Research | Company Update



Source: Vahan, Emkay Research

Exhibit 20: Consolidated reven	nue model – We	build in 5%/	10% consolid	ated revenue	/PBT CAGR ov	er FY24-27E		
(Rs mn)	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
CV revenues	439,282	301,750	472,637	657,573	733,031	728,258	793,462	853,500
Growth (%)		-31.3	56.6	39.1	11.5	-0.7	9.0	7.6
PV revenues		167,148	325,722	488,671	526,850	536,527	588,121	623,886
Growth (%)			94.9	50.0	7.8	1.8	9.6	6.1
India revenues		468,899	798,359	1,146,244	1,259,881	1,264,785	1,381,583	1,477,386
Growth (%)	-	-	70.3	43.6	9.9	0.4	9.2	6.9
CV EBITDA	(4,122)	14,870	16,357	48,108	78,701	88,119	104,340	114,369
EBITDA margin (%)		4.9	3.5	7.3	10.7	12.1	13.2	13.4
PV EBITDA	-	(4,020)	9,150	27,862	33,770	32,139	36,493	39,848
EBITDA margin (%)		(2.4)	2.8	5.7	6.4	6.0	6.2	6.4
CV EBIT	(37,875)	(2,437)	(1,248)	30,440	58,532	68,389	78,325	83,634
EBIT margin (%)	(37,073)	(0.8)	(0.3)	4.6	8.0	9.4	9.9	9.8
PV EBIT	_	(20,723)	(11,265)	5,552	10,270	5,819	7,015	6,832
EBIT margin (%)		(12.4)	(3.5)	1.1	10,270	1.1	1.2	1.1
JLR (GBP mn)	FY20	FY21	EV22	EVOD	FY24	EVOEP	EVOCE	EV07E
			FY22	FY23		FY25E	FY26E	FY27E
JLR Revenues	22,984	19,731	18,320	22,809	28,995	29,754	30,484	32,102
Growth (%)	-5.1	-14.2	-7.2	24.5	27.1	2.6	2.5	5.3
JLR EBITDA (GBP mn)	2,050	2,531	1,896	2,571	4,620	4,659	4,946	5,380
EBITDA margin (%)	8.9	12.8	10.3	11.3	15.9	15.7	16.2	16.8
JLR EBIT (incl. China JV)	140	555	(48)	529	2,445	2,560	2,658	2,831
EBIT margin (%)	0.6	2.8	-0.3	2.3	8.4	8.6	8.7	8.8
JLR PBT (GBP mn)	(17)	315	(408)	89	2,140	2,378	2,532	2,737
JLR PAT (GBP mn)	(178)	35	(793)	(53)	2,576	1,703	2,067	2,235
Consolidated Financials (Rs mn)	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
India revenues	439,282	468,899	798,359	1,146,244	1,259,881	1,264,785	1,381,583	1,477,386
JLR revenues	2,070,858	1,913,907	1,864,976	2,213,460	2,870,505	3,124,201	3,200,794	3,370,675
Consolidated revenues	2,610,680	2,497,948	2,784,536	3,459,670	4,379,278	4,471,046	4,671,852	4,944,347
Growth (%)	-13.5	-4.3	11.5	24.2	26.6	2.1	4.5	5.8
India EBITDA	(4,122)	10,850	25,507	75,971	112,471	120,258	140,834	154,217
JLR EBITDA	146,773	198,074	107,603	173,804	339,768	431,233	398,398	438,894
Consolidated EBITDA	197,258	305,553	248,132	318,296	595,603	628,700	674,040	716,478
Growth (%)	-22.9	54.9	-18.8	28.3	87.1	5.6	7.2	6.3
EBITDAM (%)								
India	(0.9)	2.3	3.2	6.6	8.9	9.5	10.2	10.4
JLR	8.9	12.8	10.3	11.3	15.9	15.7	16.2	16.8
Consolidated EBITDA margin (%)	7.6	12.2	8.9	9.2	13.6	14.1	14.4	14.5
Consol PBT	(59,698)	15,546	(62,807)	13,769	282,543	325,639	350,680	380,471
	(35,050)	13,340	(02,007)	13,709	202,545	525,055	550,000	550,471
Consol Net Debt	741,232	910,874	1,002,403	683,383	357,948	430,286	277,705	146,540
Consol FCF	-28,976	91,457	-6,555	175,774	367,328	39,086	251,432	213,024
ROE (%)	(12.1)	(2.4)	(21.5)	1.6	49.8	23.8	23.1	20.6
ROCE (%)	0.1	3.4	0.7	4.0	15.5	16.3	15.1	15.9

Source: Company, Emkay Research; Note – EPS CAGR over FY24-27E is lower due to large DTA recognition at JLR in FY24

This report is intended for team emkay@whitemarquesolutions com use and downloaded at 10/08/2024 03:10 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

## Exhibit 21: We trim FY26E/27E EPS by ~2% largely amid slightly lower margin estimates

Consolidated (Rs mn)		FY25E			FY26E				FY27E			
Consolidated (RS mn)	Earlier	Revised	% Chg	% YoY	Earlier	Revised	% Chg	% YoY	Earlier	Revised	% Chg	% YoY
JLR Volume (excl China JV)	393,820	393,820	-	(1.9)	397,512	397,512	-	0.9	412,424	412,424	-	3.8
Standalone Volume	386,599	387,849	0.3	1.0	412,539	409,130	(0.8)	5.5	433,939	431,299	(0.6)	5.4
Cons. Revenue	4,480,311	4,471,046	(0.2)	2.1	4,684,404	4,671,852	(0.3)	4.5	4,957,870	4,944,347	(0.3)	5.8
Cons. EBITDA	631,825	628,700	(0.5)	5.6	682,125	674,040	(1.2)	7.2	725,617	716,478	(1.3)	6.3
Cons. Margin (%)	14.1	14.1	(4) bps	46 bps	14.6	14.4	(13) bps	3 bps	14.6	14.5	(14) bps	0 bps
Cons. PAT	229,557	227,124	(1.1)	(29.9)	279,515	274,059	(2.0)	20.7	305,408	299,176	(2.0)	9.2
Cons. Dil. Adj. EPS (Rs)	62.4	61.7	(1.1)	(27.0)	76.0	74.5	(2.0)	20.7	83.0	81.3	(2.0)	9.2

Source: Emkay Research

## Exhibit 22: Tata Motors - SOTP-based valuation

	Basis of valuation	Equity value (Rs mn)	Equity value (Rs/share)	Contribution to SOTP (%)	Remarks
India CV	EV/EBITDA 14x	1,566,919	426	37	Similar to EV/EBITDA multiple for AL
India ICE-PV	EV/Sales 1.4x	839,285	228	20	~25% discount to MSIL's multiple of ~1.8x EV/Sales
India E-PV	Transaction value	309,750	84	7	Taking Pre-money transaction valuation fixed during the TPG deal at 40% discount — implied value of 2x P/Sales on FY26E EV revenues
JLR	EV/EBITDA 1.5x	1,192,201	324	28	In line with EV/EBITDA valuation of European peers
JLR China JV	EV/EBITDA 4x	5,142	1	0	Stake stands at 50%
Tata Sons	NAV 1x	67,692	18	2	Holding company discount at 80% as stake may not be monetized
Tata Motors Finance	1.5x FY26E P/B	119,873	33	3	Holding company discount at 20%
Tata Technologies	Мсар	177,774	48	4	20% discount to CMP
Total (Rounded off)			1,175		

Source: Emkay Research

## Exhibit 23: TTMT valuations are the least demanding among the OEM pack

OEM	EPS CAGR		P/E (x)		EV/	EBITDA (	x)	F	P/BV (x)	
<b>DEM</b>	FY24-27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Ashok Leyland	13%	21.9	18.5	16.6	12.4	11.3	10.0	6.6	6.0	5.3
Bajaj Auto	13%	37.0	33.5	30.2	28.7	25.6	22.7	13.0	12.6	12.0
TVS Motor	27%	43.2	34.2	29.4	27.7	21.7	18.5	12.8	10.2	8.2
Hero Motocorp	14%	22.8	20.4	18.2	15.9	14.1	12.4	5.6	5.1	4.9
Eicher Motors (Consol)	9%	28.7	27.1	24.6	23.3	20.6	18.6	6.1	5.3	4.6
Maruti Suzuki	9%	26.5	24.7	22.9	16.7	14.8	13.2	4.2	3.8	3.5
Tata Motors (Consol)	-2%	14.9	12.2	11.2	6.1	5.4	4.9	3.2	2.6	2.1
Mahindra & Mahindra	4%	32.3	30.4	28.5	28.0	25.0	22.2	7.3	6.2	5.4
Escorts Kubota	21%	31.6	26.6	22.9	23.6	19.1	15.9	4.1	3.7	3.3

Source: Emkay Research; Note - EPS CAGR for TTMT over FY24-27E is lower due to large DTA recognition at JLR in FY24

This report is intended for team emkay @whitemarguesolutions com use and downloaded at 10/08/2024 03:10 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

## **Tata Motors: Consolidated Financials and Valuations**

Profit & Loss					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Revenue	3,459,670	4,379,278	4,471,046	4,671,852	4,944,347
Revenue growth (%)	24.2	26.6	2.1	4.5	5.8
EBITDA	318,296	595,603	628,700	674,040	716,478
EBITDA growth (%)	28.3	87.1	5.6	7.2	6.3
Depreciation & Amortization	248,604	272,701	266,440	295,714	331,343
EBIT	69,692	322,901	362,260	378,326	385,136
EBIT growth (%)	0.0	363.3	12.2	4.4	1.8
Other operating income	0	0	0	0	0
Other income	46,332	59,499	48,789	51,229	54,815
Financial expense	102,255	99,858	85,410	78,874	59,479
РВТ	13,769	282,543	325,639	350,680	380,471
Extraordinary items	0	0	0	0	0
Taxes	7,041	(38,516)	97,411	78,888	84,955
Minority interest	2,756	4,077	5,000	2,000	1,000
Income from JV/Associates	3,364	6,998	3,895	4,267	4,660
Reported PAT	24,143	313,991	227,124	274,059	299,176
PAT growth (%)	0.0	1,200.6	(27.7)	20.7	9.2
Adjusted PAT	7,336	323,981	227,124	274,059	299,176
Diluted EPS (Rs)	1.9	84.5	61.7	74.5	81.3
Diluted EPS growth (%)	0.0	1,199.7	(24.7)	20.7	9.2
DPS (Rs)	2.0	6.0	4.6	5.3	5.6
Dividend payout (%)	31.7	7.3	7.5	7.1	6.9
EBITDA margin (%)	9.2	13.6	14.1	14.4	14.5
EBIT margin (%)	2.0	7.4	8.1	8.1	7.8
Effective tax rate (%)	51.1	(13.6)	29.9	22.5	22.3
NOPLAT (pre-IndAS)	34,056	366,920	253,895	293,219	299,139
Shares outstanding (mn)	3,830.1	3,832.5	3,679.2	3,679.2	3,679.2

Balance Sheet					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Share capital	7,660	7,665	7,665	7,665	7,665
Reserves & Surplus	445,558	841,515	1,051,662	1,306,342	1,584,732
Net worth	453,218	849,180	1,059,327	1,314,007	1,592,397
Minority interests	72,777	81,759	86,759	88,759	89,759
Deferred tax liability (net)	(37,777)	(119,557)	(220,850)	(329,932)	(448,281)
Total debt	1,256,605	985,001	932,287	838,287	496,907
Total liabilities & equity	1,744,823	1,796,384	1,857,523	1,911,120	1,730,781
Net tangible fixed assets	729,760	621,620	734,050	818,336	866,994
Net intangible assets	504,621	504,621	504,621	504,621	504,621
Net ROU assets	78,010	78,010	78,010	78,010	78,010
Capital WIP	142,745	356,984	358,114	358,114	358,114
Goodwill	8,406	8,603	8,603	8,603	8,603
Investments [JV/Associates]	60,725	60,725	63,725	66,725	69,725
Cash & equivalents	573,222	627,053	502,001	560,581	350,366
Current assets (ex-cash)	1,211,477	1,318,033	1,496,517	1,563,730	1,654,937
Current Liab. & Prov.	1,564,145	1,779,266	1,888,119	2,047,601	2,160,590
NWC (ex-cash)	(352,667)	(461,233)	(391,601)	(483,871)	(505,652)
Total assets	1,744,823	1,796,384	1,857,523	1,911,120	1,730,781
Net debt	683,383	357,948	430,286	277,705	146,540
Capital employed	1,744,823	1,796,384	1,857,523	1,911,120	1,730,781
Invested capital	968,130	751,622	933,683	925,700	952,576
BVPS (Rs)	118.3	221.6	287.9	357.1	432.8
Net Debt/Equity (x)	1.5	0.4	0.4	0.2	0.1
Net Debt/EBITDA (x)	2.1	0.6	0.7	0.4	0.2
Interest coverage (x)	0.9	0.3	0.2	0.2	0.1
RoCE (%)	4.0	15.5	16.3	15.1	15.9

Source: Company, Emkay Research

Balanca Shoot

Source: Company, Emkay Research	
---------------------------------	--

Cash flows					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
РВТ	13,769	282,543	325,639	350,680	380,471
Others (non-cash items)	383,002	371,514	351,850	374,588	390,822
Taxes paid	(31,790)	(45,163)	(198,704)	(187,970)	(203,305)
Change in NWC	(31,271)	73,252	(63,595)	89,867	20,375
Operating cash flow	353,880	679,154	419,086	631,432	593,024
Capital expenditure	(178,107)	(311,825)	(380,000)	(380,000)	(380,000)
Acquisition of business	(134)	58,150	0	0	0
Interest & dividend income	10,199	0	0	0	0
Investing cash flow	(168,042)	(228,281)	(380,000)	(380,000)	(380,000)
Equity raised/(repaid)	34,737	819	0	0	0
Debt raised/(repaid)	(202,397)	(266,965)	(52,714)	(94,000)	(341,380)
Payment of lease liabilities	(15,166)	0	0	0	0
Interest paid	(93,360)	(93,323)	(85,410)	(78,874)	(59,479)
Dividend paid (incl tax)	(1,409)	(10,591)	(23,014)	(16,977)	(19,379)
Others	55,220	7,099	0	0	0
Financing cash flow	(222,375)	(362,961)	(161,138)	(189,851)	(420,239)
Net chg in Cash	(36,537)	87,912	(122,052)	61,581	(207,215)
OCF	353,880	679,154	419,086	631,432	593,024
Adj. OCF (w/o NWC chg.)	385,151	605,902	482,681	541,565	572,649
FCFF	175,774	367,328	39,086	251,432	213,024
FCFE	83,717	267,471	(46,324)	172,558	153,544
OCF/EBITDA (%)	111.2	114.0	66.7	93.7	82.8
FCFE/PAT (%)	346.8	85.2	(20.4)	63.0	51.3
FCFF/NOPLAT (%)	516.1	100.1	15.4	85.7	71.2

Source: Company, Emkay Research

Valuations and key Ratios Y/E Mar FY23 **FY24** FY25E FY26E FY27E P/E (x) 484.4 11.0 15.0 12.5 11.4 P/CE(x) 13.9 6.0 6.9 6.0 5.4 P/B (x) 4.2 3.2 2.6 2.1 7.8 EV/Sales (x) 1.2 0.9 0.9 0.8 0.7 EV/EBITDA (x) 13.3 5.5 6.6 6.1 5.0 EV/EBIT(x) 60.8 12.1 10.6 9.8 9.2 EV/IC (x) 4.4 5.2 4.1 4.0 3.7 FCFF yield (%) 4.1 9.4 1.0 6.8 6.0 FCFE yield (%) 2.4 7.5 (1.4)5.1 4.5 Dividend yield (%) 0.2 0.6 0.5 0.6 0.6 DuPont-RoE split Net profit margin (%) 0.2 7.4 5.1 5.9 6.1 Total asset turnover (x) 1.8 2.5 2.4 2.5 2.7 Assets/Equity (x) 4.3 2.7 1.9 1.6 1.3 RoE (%) 1.6 49.8 23.8 23.1 20.6 DuPont-RoIC NOPLAT margin (%) 1.0 8.4 5.7 6.3 6.1 IC turnover (x) 3.6 5.8 4.8 5.0 5.2 RoIC (%) 3.0 42.7 30.1 31.5 31.9 **Operating metrics** Core NWC days (37.2) (38.4) (32.0) (37.8) (37.3) Total NWC days (38.4) (37.2) (32.0) (37.8) (37.3) Fixed asset turnover 1.0 1.2 1.2 1.1 1.1 Opex-to-revenue (%) 25.3 24.1 24.6 23.1 23.0

Source: Company, Emkay Research

This report is intended for team emkay @ whitemarquesolutions com use and downloaded at 10/08/2024 03:10 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

## **RECOMMENDATION HISTORY - DETAILS**

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
18-Sep-24	962	1,175	Buy	Chirag Jain
02-Aug-24	1,097	1,175	Add	Chirag Jain
10-Jul-24	1,006	1,050	Add	Chirag Jain
12-Jun-24	989	1,050	Add	Chirag Jain
11-May-24	1,047	950	Reduce	Chirag Jain
18-Apr-24	971	950	Reduce	Chirag Jain
04-Mar-24	987	950	Reduce	Chirag Jain
03-Feb-24	879	925	Add	Chirag Jain
10-Jan-24	808	900	Add	Chirag Jain
30-Nov-23	706	760	Add	Chirag Jain
03-Nov-23	648	760	Buy	Chirag Jain
26-Jul-23	641	750	Buy	Chirag Jain
08-Jun-23	560	605	Buy	Chirag Jain
13-May-23	516	565	Buy	Chirag Jain

**RECOMMENDATION HISTORY - TREND** 





Source: Company, Emkay Research

## GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014, EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information. it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

bis report is intended for team emkay@whitemarguesolutions com use and downloaded at 10/08/2024 03:10 Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singa analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore. on Distribution. In Singapore, this research report or research

### RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

## ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup>An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

## COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGESL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in 1. the securities recommended in this report as of October 8, 2024
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report 2. Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report З during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities 4. recommended in this report as of October 8, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the 5. subject company at the end of the month immediately preceding the October 8, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months. 6.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for
- investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

## **Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

### Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkavglobal.com

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 10/08/2024 03:10 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

### **OTHER DISCLAIMERS AND DISCLOSURES:**

# Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject Company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates for the subject company in the past twelve months.